Drug Trial Radar · NCT00068003
Harvesting Cells for Experimental Cancer Treatments
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
7,000
Planned (sponsor's estimate)
Start
Sep 8, 2003
Primary completion
Not stated
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Sep 4, 2003
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product. Eligibility: Patients must be eligible for a NCI Surgery Branch Treatment Protocol Normal Volunteers must meet the criteria for blood donation Design Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol. There is no required follow up for normal volunteers. ...
Conditions
- Melanoma
- Gastrointestinal Cancer
- Metastatic Cancer
- Breast Cancer
- Non-Small Cell Lung Cancer
Interventions
Anti-CD19 CAR PBLDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Generating anti-tumor patient lymphocytes ex vivoTime frame: Approximately 20 years
- To conduct genomic, proteomic, and immunologic research studiesTime frame: Approximately 20 years
- To obtain autologous blood, stem cells, and/or tumor tissue from patients currently with cancerTime frame: Approximately 20 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.